[Seite 129↓]

VI. Literaturverzeichnis

Allison AC und Eugui EM (1993a) Immunosuppressive and other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate Mofetil. Immunol Rev 136: 5-28.

Allison AC und Eugui EM (1993b) Mycophenolate mofetil, a rational designed immunosuppressive drug . Clin Transplantation 7: 96-112.

Allison AC und Eugui EM (1994) Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 26: 3205-3210.

Allison AC, Eugui EM und Sollinger HW (1993) Mycophenolate Mofetil (RS-61443): Mechanisms of Action and Effects in Transplantation. Transplant Rev 7: 129-139.

Azuma H, Binder J, Heemann U, Schmid C, Tullius SG und Tilney NL (1995) Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 59: 460-466.

Bandoh T, Mitani H, Niihashi M, Kusumi Y, Ishikawa J, Kimura M, Totsuka T, Sakurai I und Hayashi S (1996) Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. Eur J Pharmacol 315: 37-42.

Barnard C (1967) The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 41: 1271-1274.

Barten MJ, Gummert JF, van Gelder T, Shorthouse R und Morris RE (2001) Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by mmunosuppressive drugs in vitro. J Immunol Methods 253: 95-112.

Barten MJ, van Gelder T, Gummert JF, Boeke K, Shorthouse R, Billingham M und Morris RE (submitted) Pharmacodynamics of mycopheloate mofetil (CellCept) after heart transplantation: New mechanism of action and correlation with histologic severity of graft rejection. Am J Transpl .


[Seite 130↓]

Batts KP (1999 ) Acute and chronic hepatic allograft rejection: pathology and classification. Liver Transpl Surg 5: S21-29.

Bechstein WO, Schilling M, Steele DM, Hullett DA und Sollinger HW (1993) RS-61443/cyclosporine combination therapy prolongs canine liver allograft survival. Transplant Proc 25: 702-703.

Belzer FO, Ashby BS und Dunphy JE (1967) 24-hour and 72-hour preservation of canine kidneys. Lancet 2: 536.

Billingham ME (1994) Pathology and etiology of chronic rejection of the heart. Clin Transplant 8: 289-292.

Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, Snovar DC, Winters GL und Zerbe A (1990) A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 9: 587-593.

Blindt R, Bosserhoff AK, Zeiffer U, Krott N, Hanrath P und vom Dahl J (2000) Abciximab inhibits the migration and invasion potential of human coronary artery smooth muscle cells . J Mol Cell Cardiol 32: 2195-2206.

Borel J, Feurer C, Gubler H und Stahelin H (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6: 468-475.

Brettschneider L, Kolff J, Smith G, Martin A, Taylor P und Starzl T (1968) An evaluation of perfusion constituents in liver preservation. Surg Forum 19: 354-356.

Brewin TB, Cole MP, Jones CT, Platt DS und Todd ID (1972) Mycophenolic acid (NSC-129 185): preliminary clinical trials. Cancer Chemother Rep 56: 83-87.

Brunet M, Martorell J, Oppenheimer F, Vilardell J, Millan O, Carrillo M, Rojo I und Corbella J (2000) Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transpl Int 13: S301-305.


[Seite 131↓]

Budde K, Glander P, Bauer S, Braun K, Waiser J, Fritsche L, Mai I, Roots I und Neumayer HH (2000) Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 38: 1213-1216.

Bullingham R, Monroe S, Nicholls A und Hale M (1996a) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36 : 315-324.

Bullingham RE, Nicholls A und Hale M (1996b) Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Pro c 28 : 925-929.

Bullingham RE, Nicholls AJ und Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34: 429-455.

Calne R, White D, Rolles K, Smith D und Herbertson B (1978a) Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A . Lancet 1: 1183-1185.

Calne R, White D, Thiru S, Evans D, McMaster P, Dunn D, Craddock G, Pentlow B und Rolles K (1978b) Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2: 1323-1327.

Campistol J, Mazuecos A, Segura J, Osuna A, Herrero J, Andres A, Oppenheimer F, Gomez dlCA, Martinez M und Morales J (1999) Mycophenolate mofetil slows the decline of renal function in patients with biopsy-proven chronic rejection: a collaborative pilot study. Transplant Proc 31: 2267-2269.

Carrel A (1914) The transplantation of organs. N Y Med 99: 839-846.

Chapman FA, Cramer DV und Makowka LS (1994 ) Heterotopic Heart Transplantation in Rodents, in Handbook of Animal Models in Transplantation Research (Cramer DV, Podesta L und Makowka LS eds) 149-160, CRC Press Inc., Boca Raton.

Chellman GJ, Lukas VS, Eugui EM, Altera KP, Almquist SJ und Hilliard JK (1992) Activation of B virus (Herpesvirus simiae) in chronically immunosuppressed cynomolgus monkeys . Lab Anim Sci 42 : 146-151.


[Seite 132↓]

Corsini A, Bernini F, Quarato P, Donetti E, Bellosta S, Fumagalli R, Paoletti R und Soma VM (1996) Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 87: 458-468.

Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R und Paoletti R (1995) Pathogenesis of atherosclerosis and the role of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 76: 21A-28A.

Costanzo MR, Naftel DC, Pritzker MR, Heilman JK, 3rd, Boehmer JP, Brozena SC, Dec GW, Ventura HO, Kirklin JK, Bourge RC und Miller LW (1998) Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 17: 744-753.

Dal Bello B, Klersy C, Grossi P, Gavazzi A, Ippoliti G, Rinaldi M, Vigano M und Arbustini E (1998 ) Combined human cytomegalovirus and hepatitis C virus infections increase the risk of allograft vascular disease in heart transplant recipients. Transplant Proc 30 : 2086-2090.

D'Alessandro A, Rankin M, McVey J, Hafez G, Sollinger H, Kalayoglu M und Belzer F (1993) Prolongation of canine intestinal allograft survival with RS-61443, cyclosporine, and prednisone . Transplantation 55 : 695-701.

Dausset J (1958) Iso-leuco-anticorps. Acta Haematol 20 : 156-166.

Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, Fung J, Gouw A, Gustafsson B, Haga H, Harrison D, Hart J, Hubscher S, Jaffe R, Khettry U, Lassman C, Lewin K, Martinez O, Nakazawa Y, Neil D, Pappo O, Parizhskaya M, Randhawa P, Rasoul-Rockenschaub S, Reinholt F, Reynes M, Robert M, Tsamandas A, Wanless I, Wiesner R, Wernerson A, Wrba F, Wyatt J und Yamabe H (2000) Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 31: 792-799.

Di ML, Bertoni E, Rosati A, Zanazzi M, Piperno R, Moscarelli L, Toti G, Casini F, Bandini S und Salvadori M (2000 ) Mycophenolate mofetil (MMF) in the treatment of chronic renal rejection. Clin Nephrol 53: 33-34.


[Seite 133↓]

Eckhoff D, McGuire B, Frenette L, Contreras J, Hudson S und Bynon J (1998) Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation . Transplantation 65 : 180-187.

Epinette WW, Parker CM, Jones EL und Greist MC (1987 ) Mycophenolic acid for psoriasis. J Amer Acad Dermatol 17: 962-971.

Eugui E (2001) persönliche Kommunikation; interne Untersuchungsergebnisse Roche, Bioscience , Palo Alto, CA, USA.

Eugui E, Almquist S, Muller C und Allison A (1991) Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 33: 161-173.

European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321-1325.

Fellstrom B, Backman U, Larsson E und Zezina L (1999) Immunologic and nonimmunologic risk factors of chronic rejection. Transplant Proc 31: 1304-1305.

Ferraris J, Tambutti M, Redal M, Bustos D, Ramirez J und Prigoshin N (2000) Conversion from azathioprine [correction of azathioprina] to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation 70 : 297-301.

Foegh ML, Asotra S, Howell MH und Ramwell PW (1994) Estradiol inhibition of arterial neointimal hyperplasia after balloon injury . J Vasc Surg 19: 722-726.

Fraser-Smith E, Rosete J und Schatzman R (1995) Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis model. J Pharmacol Exp Ther 275: 1204-1208.

Gibson T und Medawar PB (1942) Fate of skin homografts in man . J Anatom 77 : 29-57.

Glanemann M, Klupp J, Langrehr J, Platz K, Schroer G, Raakow R, Stange B, Settmacher U, Bechstein W und Neuhaus P (2001) Mycophenolate mofetil is superior in combination with tacrolimus compared to cyclosporine for immunosuppressive therapy after liver transplantation [In Process Citation]. Transplant Proc 33: 1069-1070.


[Seite 134↓]

Glanemann M, Klupp J, Langrehr J, Schroer G, Platz K, Stange B, Settmacher U, Bechstein W und Neuhaus P (2000) Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with cyclosporine A. Transplant Proc 32: 522-523.

Glicklich D, Gupta B, Schurter-Frey G, Greenstein S, Schechner R und Tellis V (1998) Chronic renal allograft rejection: no response to mycophenolate mofetil. Transplantation 66 : 398-399.

Gosio B (1896) Ricerche batteriologiche e chimiche sulle alterazoni del mais. Rivista d'Igiene e Sanita Publica Ann 7: 825-868.

Gregory C, Huang X, Pratt R, Dzau V, Shorthouse R, Billingham M und Morris R (1995) Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 59 : 655-661.

Gregory CR, Huie P, Billingham ME und Morris RE (1993a) Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 55: 1409-1418.

Gregory CR, Pratt RE, Huie P, Shorthouse R, Dzau VJ, Billingham ME und Morris RE (1993b) Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc 25: 770-771.

Gruessner R, Sutherland D, Drangstveit M, Wrenshall L, Humar A und Gruessner A (1998) Mycophenolate mofetil in pancreas transplantation. Transplantation 66 : 318-323.

Gummert J, Ikonen T, Briffa N, Honda Y, Hayase M, Perlroth J, Kobayashi Y, Hausen B, Barlow C, Billingham M, Fitzgerald P, Yock P, Robbins R und Morris R (1998) A new large-animal model for research of graft vascular disease. Transplant Proc 30: 4023.


[Seite 135↓]

Gummert JF, Barten MJ, Sherwood SW, van Gelder T und Morris RE (1999a) Pharmacodynamics of immunosuppression by mycophenolic acid: Inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol Exp Ther 291: 1100-1112.

Gummert JF, Christians U, Barten M, Silva H und Morris RE (1999b) High-performance liquid chromatographic assay with a simple extraction procedure for sensitive quantification of mycophenolic acid in rat and human plasma. J Chromat B 721: 321-326.

Hager PW, Collart FR, Huberman E und Mitchell BS (1995) Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 49: 1323-1329.

Hamburger J, Vayesse I und Crosnier J (1959) Transplantation of a kidney between non-monozygotic twins after irradiation of the recipient . Presse Med 67: 1771-1775.

Hamilton D und Reid W (1984) Yu Yu Voronoy and the first human kidney allograft. Surg Gynecol Obstet 159 : 289-294.

Hausen B, Boeke K, Berry GJ und Morris RE (2001) Viral Serine Proteinase Inhibitor (Serp-1) Effectively Decreases the Incidence of Graft Vasculopathy in Heterotopic Heart Allografts1. Transplantation 72 : 364-368.

Hayry P (1998) Chronic allograft vasculopathy: new strategies for drug development. Transplant Proc 30: 3989-3990.

Hayry P, Mennander A, Tiisala S, Halttunen J, Yilmaz S und Paavonen T (1991 ) Rat aortic allografts: an experimental model for chronic transplant arteriosclerosis. Transplant Proc 23 : 611-612.

Hebert M, Ascher N, Lake J, Emond J, Nikolai B, Linna T und Roberts J (1999) Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 67: 707-712.

Hullett DA, Geraghty JG, Stoltenberg RL und Sollinger HW (1996) The impact of acute rejection on the development of intimal hyperplasia associated with chronic rejection. Transplantation 62: 1842-1846.


[Seite 136↓]

Hullett DA und Sollinger HW (1993) Mycophenolate mofetil and brequinar sodium: new immunosuppressive agents . Transplant Proc 25: 45-47.

Ikonen T, Briffa N, Gummert J, Honda Y, Hayase M, Hausen B, Billingham M, Yock P, Robbins R und Morris R (2000a) Multidimensional assessment of graft vascular disease (GVD) in aortic grafts by serial intravascular ultrasound in rhesus monkeys. Transplantation 70: 420-429.

Ikonen T, Gummert J, Hayase M, Honda Y, Hausen B, Christians U, Berry G, Yock P und Morris R (2000b) Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 70 : 969-975.

Ikonen T, Gummert J, Honda Y, Hayase M, Perlroth J, Hausen B, Barlow C, Fitzgerald P, Yock P und Morris R (1999) Development of models of graft vascular disease in nonhuman primates: evaluation of GVD by intravascular ultrasound in a new cynomolgus model with arterial allograft exchange . Transplant Proc 31 : 687.

Ikonen T, Gummert J, Serkova N, Hayase M, Honda Y, Kobayase Y, Hausen B, Yock P, Christians U und Morris R (2000c) Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. Transpl Int 13 Suppl 1: S314-320.

Isobe M, Suzuki J, Morishita R, Kaneda Y und Amano J (2000) Gene therapy for heart transplantation-associated coronary arteriosclerosis. Ann N Y Acad Sci 902: 77-83.

Jain A, Hamad I, Rakela J, Dodson F, Kramer D, Demetris J, McMichael J, Starzl T und Fung J (1998) A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 66: 1395-1398.

Jain A, Reyes J, Kashyap R, Dodson S, Demetris A, Ruppert K, Abu-Elmagd K, Marsh W, Madariaga J, Mazariegos G, Geller D, Bonham C, Gayowski T, Cacciarelli T, Fontes P, Starzl T und Fung J (2000) Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 232: 490-500.


[Seite 137↓]

Jain A, Venkataramanan R, Hamad IS, Zuckerman S, Zhang S, Lever J, Warty VS und Fung JJ (2001) Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 41 : 268-276.

Jirasiritham S, Sumethkul V, Mavichak V, Chiewsilp P, Leenanupunth C und Kochakarn W (1998 ) Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience. Transplant Proc 30: 3576-3577.

Kahan BD (1983 ) Cosmas and Damian revisited. Transplant Proc 15: 2211-2216.

Kahan BD (1988) Pien Ch'iao, the legendary exhange of hearts: traditional Chinese medicine and the modern area of cyclosporine . Transplant Proc 20: 3-12.

Kahl A, Bechstein W, Lorenz F, Steinberg J, Pohle C, Kampf D, Muller A, Settmacher U, Neuhaus P und Frei U (2001 ) Long-term prednisolone withdrawal after pancreas and kidney transplantation in patients treated with ATG, tacrolimus, and mycophenolate mofetil . Transplant Proc 33: 1694-1695.

Kato T, Ruiz P, De FW, Weppler D, Khan F, Pinna A, Nery J und Tzakis A (1999) Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection . Transplant Proc 31: 396.

Kirklin JK, Bourge RC, Naftel DC, Morrow WR, Deierhoi MH, Kauffman RS, White Williams C, Nomberg RI, Holman WL und Smith DCJ (1994) Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 13: 444-450.

Klupp J, Bechstein W, Platz K, Keck H, Lemmens H, Knoop M, Langrehr J, Neuhaus R, Pratschke J und Neuhaus P (1997) Mycophenolate mofetil added to immunosuppression after liver transplantation--first results. Transpl Int 10: 223-228.

Klupp J, Dambrin C, Regieli J, van Gelder T, Shorthouse R und Morris RE (2001a) New approach in drug development: whole blood pharmacodynamic assays reflect biological activities of tacrolimus. Transplant Proc 33: 2172.


[Seite 138↓]

Klupp J, Dambrin C, van Gelder T, Regieli J und Morris RE (submitted-a) Flow cytometric quantitation of immunosuppressive drug effects on T, B cell and monocyte function. Am J Transpl : submitted.

Klupp J, Glanemann M, Bechstein W, Platz K, Langrehr J, Keck H, Settmacher U, Radtke C, Neuhaus R und Neuhaus P (1999) Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc 31: 1113-1114.

Klupp J, van Gelder T, Dambrin C, Boeke K, Regieli J, Billingham ME und Morris RE (2001b) Novel pharmacodynamic assays of lymphocyte function and proliferation in peripheral blood are affected by MMF dose schedule and correlate with histological severity of rejection in rat heart transplant recipients [abstract]. Am J of Transpl 1: 222.

Klupp J, van Gelder T, Dambrin C, Regieli J, Boeke K, Billingham ME und Morris RE (2001c) Mycophenolate mofetil pharmacodynamics and pharmacokinetics correlate with rejection score in a BN-to-LEW heterotopic heart transplant model. Transplant Proc 33 : 2170-2171.

Klupp J, van Gelder T, Dambrin C, Regieli J, Boeke K, Billingham ME und Morris RE (submitted-b) Sustained supression of peripheral blood immune functions by treatment with mycophenolate mofetil throughout the dosing interval correlates with reduced histologic severity of heart allograft rejection. J Heart Lung Transplant : submitted.

Klupp J, van Gelder T, Regieli J, Shorthouse R, Kavanau K und Morris RE (2000) Development of a novel pharmacodynamic assay in non-human primates. Transplantation 69: S124.

Kobashigawa J (1998) Mycophenolate mofetil in cardiac transplantation. Curr Opin Cardiol 13: p117-121.

Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F und Valantine H (1998 ) A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators . Transplantation 66: 507-515.


[Seite 139↓]

Küss R, Legrain M, Mathe G, Nedey R und Camey M (1962 ) Homologous human kidney transplantation. Experience with six patients. Postgrad Med J 38 : 528-531.

Landsteiner L (1931) ABO red blood group system . Science 73: 403-409.

Langman LJ, LeGatt DF, Halloran PF und Yatscoff RW (1996) Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 62: 666-672.

Langman LJ, Nakakura H, Thliveris JA, LeGatt DF und Yatscoff RW (1997) Pharmacodynamic monitoring of mycophenolic acid in rabbit heterotopic heart transplant model. Ther Drug Monit 19: 146-152.

Larsen RL, Applegate PM, Dyar DA, Ribeiro PA, Fritzsche SD, Mulla NF, Shirali GS, Kuhn MA, Chinnock RE und Shah PM (1998) Dobutamine stress echocardiography for assessing coronary artery disease after transplantation in children. J Am Coll Cardiol 32: 515-520.

Little DM, Stoltenberg RL, Hullett DA und Sollinger HW (1996) Effect of Neoral or cyclosporine on the development of chronic rejection in an aortic allograft rat model. Transplant Proc 28 : 880-881.

Lucas A, Dai E, Liu L, Guan H, Nash P, McFadden G und Miller L (2000) Transplant vasculopathy: viral anti-inflammatory serpin regulation of atherogenesis. J Heart Lung Transplant 19 : 1029-1038.

McDiarmid S (1996) Mycophenolate mofetil in liver transplantation. Clin Transplant 10: 140-145.

Medawar PB (1944 ) The behavior and fate of skin autografts and skin homografts in rabbits. J Anatom 78: 176-196.

Meiser BM, Pfeiffer M, Schmidt D, Reichenspurner H, Ueberfuhr P, Paulus D, von Scheidt W, Kreuzer E, Seidel D und Reichart B (1999) Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring . J Heart Lung Transplant 18: 143-149.


[Seite 140↓]

Mennander A, Tiisala S, Halttunen J, Yilmaz S, Paavonen T und Hayry P (1991) Chronic rejection in rat aortic allografts. An experimental model for transplant arteriosclerosis. Arterioscler Thromb 11: 671-680.

Merion R, Henry M, Melzer J, Sollinger H, Sutherland D und Taylor R (2000) Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation. Transplantation 70: 105-111.

Merrill JP, Murray JE und Harrison JH (1960 ) Successful homotransplantation of the kidney between non-identical twins . N Engl J M ed 262: 1251.

Mohacsi P, Tuller D, Hulliger B und Wijngaard P (1997) Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor . J Heart Lung Transplant 16: 484-492.

Moon JI, Kim YS, Kim MS, Kim EH, Kim HJ, Kim SI und Park K (2000) Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study. Transplant Proc 32 : 2026-2027.

Morishita R, Aoki M und Kaneda Y (2000) Oligonucleotide-based gene therapy for cardiovascular disease: are oligonucleotide therapeutics novel cardiovascular drugs? Curr Drug Targets 1: 15-23.

Morris R, Wang J, Blum J, Flavin T, Murphy M, Almquist S, Chu N, Tam Y, Kaloostian M, Allison A und et a (1991) Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 23: 19-25.

Morris RE (2001 ) Persönliche Kommunikation, in.

Morris RE, Hoyt EG, Eugui EM und Allison AC (1989 ) Prolongation of rat heart allograft survival by RS-61443. Surg Forum 40 : 337-338.


[Seite 141↓]

Morris RE, Hoyt EG, Murphy MP, Eugui EM und Allison AC (1990) Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 22 : 1659.

Morris RE, Huang X, Gregory CR, Billingham ME, Rowan R, Shorthouse R und Berry GJ (1995 ) Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 27: 2068-2069.

Morris RE und Wang J (1991) Comparison of the immunosuppressive effects of mycophenolic acid and the morpholinoethyl ester of mycophenolic acid (RS-61443) in recipients of heart allografts. Transplant Proc 23 : 493-496.

Murray JE, Merrill JP, Dammin GJ und Harrison JH (1960 ) Study of transplantation immunity after total body irradition: clinical and experimental investigations. Surgery 48: 272.

Murray JE, Merrill JP und Harrison JH (1955) Renal homotransplantation in identical twins. Surg Forum 6: 432.

Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE und Cohen LH (1997) Inhibition of proliferation of human smooth muscle cells by various HMG- CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1345: 259-268.

Nicholls AJ (1998) Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection . Clin Biochem 31: 329-333.

Odorico J, Leverson G, Becker Y, Pirsch J, Knechtle S, D'Alessandro A und Sollinger H (1999 ) Pancreas transplantation at the University of Wisconsin. Clin Transpl : 199-210.

Odorico J, Pirsch J, Knechtle S, D'Alessandro A und Sollinger H (1998 ) A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation 66: 1751-1759.


[Seite 142↓]

O'Flaherty WD (1975 ) Hindu Myths Translated. Penguin Books Ltd., London.

O'Hair DP, McManus RP und Komorowski R (1994) Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 58: 1311-1315.

Ono K und Lindsey ES (1969 ) Improved technique of heart transplantation in rats. J Thoracic Cardiovasc Surg 57 : 225-229.

Orbaek AH (1999) Heart allograft vascular disease: an obliterative vascular disease in transplanted hearts . Atherosclerosis 142: 243-263.

Pahl E, Miller SA, Griffith BP und Fricker FJ (1995) Occult restrictive hemodynamics after pediatric heart transplantation. J Heart Lung Transplant 14: 1109-1115.

Pardo MF, Panizo A, Lozano M, Herreros J und Mejia S (1997) Role of endomyocardial biopsy in the diagnosis of chronic rejection in human heart transplantation. Clin Transplant 11: 426-431.

Platz KP, Bechstein WO, Eckhoff DE, Suzuki Y und Sollinger HW (1991a) RS-61443 reverses acute allograft rejection in dogs. Surger y 110: 736-741.

Platz KP, Eckhoff DE, Hullett DA und Sollinger HW (1991b) Prolongation of dog renal allograft survival by RS-61443, a new, potent immunosuppressive agent. Transplant Proc 23: 497-498.

Platz KP, Eckhoff DE, Hullett DA und Sollinger HW (1991c) RS-61443 studies: review and proposal. Transplant Proc 23 : 33-35.

Plissonnier D, Nochy D, Poncet P, Mandet C, Hinglais N, Bariety J und Michel JB (1995 ) Sequential immunological targeting of chronic experimental arterial allograft. Transplantation 60: 414-424.

Qi S, Chen H, Xu D und Daloze P (1996) Prolongation of pancreas allograft survival by mycophenolate mofetil in the rat. Transplant Proc 28: 932-933.


[Seite 143↓]

Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y und et al. (1999) The Banff 97 working classification of renal allograft pathology. Kidney Int 55 : 713-723.

Raisanen-Sokolowski A, Aho P, Myllarniemi M, Kallio E und Hayry P (1995a) Inhibition of early chronic rejection in rat aortic allografts by mycophenolate mofetil (RS61443). Transplant Proc 27 : 435.

Raisanen-Sokolowski A, Myllarniemi M und Hayry P (1994) Effect of mycophenolate mofetil on allograft arteriosclerosis (chronic rejection). Transplant Proc 26 : 3225.

Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, Yilmaz S, Kallio E und Hayry P (1995b) Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol 3: 342-351.

Rickenbacher PR, Kemna MS, Pinto FJ, Hunt SA, Alderman EL, Schroeder JS, Stinson EB, Popp RL, Chen I, Reaven G und Valantine HA (1996) Coronary artery intimal thickening in the transplanted heart. An in vivo intracoronary untrasound study of immunologic and metabolic risk factors. Transplantation 61: 46-53.

Ross R (1990) Mechanisms of atherosclerosis--a review. Adv Nephrol Necker Hosp 19 : 79-86.

Ross R, Glomset J und Harker L (1977) Response to injury and atherogenesis. Am J Pathol 86 : 675-684.

Schmid C, Heemann U, Azuma H und Tilney NL (1995) Comparison of rapamycin, RS 61443, cyclosporine, and low-dose heparin as treatment for transplant vasculopathy in a rat model of chronic allograft rejection. Transplant Proc 27: 438-439.

Schreiber T, Greenstein S, Kim D, Calderon T, Sun S, Schechner R, Tellis V und Berman J (1998) Effect of mycophenolate mofetil on atherosclerosis in a rabbit model: initial histologic and immunohistochemical analyses. Transplant Proc 30: 961-962.


[Seite 144↓]

Schütz E, Shipkova M, Armstrong V, Wieland E und Oellerich M (1999) Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 45: 419-422.

Schwartz R und Dameshek W (1959) Drug-induced immunological tolerance. Nature 83: 1682-1683.

Shaw LM, Korecka M, DeNofrio D und Brayman KL (2001) Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem 34: 17-22.

Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, Morris RE, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P und Morris RG (1998 ) Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 31 : 317-322.

Shifrine M, Taylor NJ, Rosenblatt LS und Wilson FD (1978 ) Comparison of whole blood and purified canine lymphocytes in a lymphocyte-stimulation microassay. Am J Vet Res 39 : 687-690.

Shumway N, Angell W und Wuerflein R (1967a) Progress in transplantation of the heart. Transplantation 5: 900-903.

Shumway N, Angell W und Wuerflein R (1967b ) Recent advances in cardiac replacement . Surgery 62: 794-796.

Sibley RK (1994) Morphologic features of chronic rejection in kidney and less commonly transplanted organs . Clin Transplant 8: 293-298.

Solez K (1994) International standardization of criteria for histologic diagnosis of chronic rejection in renal allografts . Clin Transplant 8: 345-350.

Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF und et al. (1993) International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 44: 411-422.


[Seite 145↓]

Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60: 225-232.

Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG und Kauffman RS (1992) RS-61443 - A phase I clinical trial and pilot rescue study. Transplantation 53: 428-432.

Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IMF, Seixas AC, Staico R, Mattos LA, Sousa AGMR, Falotico R, Jaeger J, Popma JJ und Serruys PW (2000 ) Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study. Circulation 102: r54-r57.

Stanford University (1999) Administrative Panel on Laboratory Animal Care (A-PLAC); http://www.stanford.edu/dept/DoR/A-PLAC/.

Starzl T, Brettschneider L, Penn I, Schmidt R, Bell P, Kashiwagi N, Townsend C und Putnam C (1969) A trial with heterologous antilymphocyte globulin in man. Transplant Proc 1: 448-454.

Starzl T, Marchioro T, Porter K und Brettschneider L (1967) Homotransplantation of the liver. Transplantation 5: 790-803.

Steele D, Hullett D, Bechstein W, Kowalski J, Smith L, Kennedy E, Allison A und Sollinger H (1993) Effects of immunosuppressive therapy on the rat aortic allograft model . Transplant Proc 25: 754-755.

Stoltenberg R, Geraghty J, Steele DM, Kennedy E, Hullett DA und Sollinger HW (1994) Cyclosporine inhibits intimal hyperplasia in rat aortic allografts. Transplant Proc 26 : 2569-2570.

Stoltenberg RL, Geraghty J, Steele DM, Kennedy E, Hullett DA und Sollinger HW (1995 ) Inhibition of intimal hyperplasia in rat aortic allografts with cyclosporine. Transplantation 60: 993-998.

Stratta R (1997 ) Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group. Transplant Proc 29: 654-655.


[Seite 146↓]

Suzuki J, Isobe M, Morishita R, Nishikawa T, Amano J und Kaneda Y (2000) Antisense Bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts . Cardiovasc Res 45: 783-787.

Taylor DO, Ensley RD, Olsen SL, Dunn D und Renlund DG (1994) Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant 13 : 571-582.

Tullius SG, Hancock WW, Heemann U, Azuma H und Tilney NL (1994) Reversibility of chronic renal allograft rejection. Critical effect of time after transplantation suggests both host immune dependent and independent phases of progressive injury. Transplantation 58: 93-99.

UNOS (1999) Annual report of the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data 1989-1998; http://www.unos.org/data/anrpt_main.htm.

Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A, Griffith BP, Hardesty RL, Trento A und Bahnson HT (1987) Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 76: 827-834.

van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD und Nicholls AJ (1999) A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68 : 261-266.

van Gelder T, Klupp J, Kavanau K, Koransky M und Morris RE (in preparation) Pharmacodynamic effects of mycophenolate mofetil treatment - a study in healthy volunteers. in preparation .

van Gelder T, Klupp J, Kavanau K und Morris RE (2000) Novel mechanisms of action of mycophenolic acid (MPA): Inhibition of expression of CD28 and CD154 costimulatory molecules and induction of apoptosis in vivo in humans after treatment with mycophenolate mofetil (MMF). Transplantation 69: S393.

Ventura HO, Mehra MR, Smart FW und Stapleton DD (1995) Cardiac allograft vasculopathy: current concepts. Am Heart J 129 : 791-799.


[Seite 147↓]

Vu M, Qi S, Xu D, Wu J, Peng J, Daloze P, Sehgal S, Leduc B und Chen H (1998) Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 66 : 1575-1580.

Weis M und von Scheidt W (1997) Cardiac allograft vasculopathy: a review. Circulation 96 : 2069-2077.

Weppler D, Khan R, Fragulidis G, Nery J, Ricordi C und Tzakis A (1996) Status of liver and gastrointestinal transplantation at the University of Miami., in Clin Transpl 187-201.

Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, McMaster P, Kalayoglu M, Levy G, Freeman R, Bismuth H, Neuhaus P, Mamelok R und Wang W (2001) A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 7: 442-450.

Wiesner RH (1994) Advances in diagnosis, prevention, and management of hepatic allograft rejection. Clin Chem 40: 2174-2185.

Wong KC und Lien-The W (1973) The History of Chinese Medicine . AMS Press, New York .


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
17.09.2004